Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.4K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.0K
Overview
83.0K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Replicative Cell Senescence02:15

Replicative Cell Senescence

4.2K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026
Same author

Demonstration of Gliadin Penetration into the Epidermis by Tape Stripping as Prerequisite for Percutaneous Sensitisation in Wheat Allergy.

International journal of molecular sciences·2026
Same author

mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.

Nature biotechnology·2026
Same author

The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.

The Annals of thoracic surgery·2026
Same author

Dendritic Cell Heterogeneity Tailored to Their Function.

Immunological reviews·2026
Same author

A Human Lymph node-on-a-Chip for Personalized Evaluation of Vaccine Immunogenicity.

Research square·2026
Same journal

Six ways to put the public at the heart of science and policy.

Nature·2026
Same journal

The complex truth about trust in science.

Nature·2026
Same journal

Have people stopped trusting science? The data tell a surprising story.

Nature·2026
Same journal

How FAIR data are helping to build trust in science.

Nature·2026
Same journal

Scientists should recognize their own political biases to build public trust.

Nature·2026
Same journal

Harmonizing standards and resources for the medical genome.

Nature·2026
See all related articles

Related Experiment Video

Updated: Dec 24, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.3K

A conserved dendritic-cell regulatory program limits antitumour immunity.

Barbara Maier1,2,3, Andrew M Leader1,2,3, Steven T Chen1,2,3

  • 1The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Nature
|April 10, 2020
PubMed
Summary
This summary is machine-generated.

Researchers identified a new type of dendritic cell (DC) that hinders anti-cancer immunotherapy. Blocking a specific signaling pathway in these mature DCs enriched in immunoregulatory molecules (mregDCs) restored anti-tumor immunity and reduced tumor growth.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.3K

Related Experiment Videos

Last Updated: Dec 24, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.3K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.3K

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Biology

Background:

  • Checkpoint blockade therapies have revolutionized cancer treatment but are ineffective for many patients.
  • Conventional type 1 dendritic cells (DC1s) are crucial for priming CD8+ T cell responses and are linked to better cancer survival.
  • The presence of DC1s in tumors resistant to checkpoint blockade suggests altered DC function in these lesions.

Purpose of the Study:

  • To investigate the functional state of dendritic cells (DCs) in tumors resistant to checkpoint blockade.
  • To identify novel DC subsets and their roles in regulating anti-tumor immunity.
  • To uncover molecular mechanisms underlying DC dysfunction in cancer.

Main Methods:

  • Single-cell RNA sequencing was employed on human and mouse non-small-cell lung cancer samples.
  • Characterization of a newly identified DC subset, termed 'mature DCs enriched in immunoregulatory molecules' (mregDCs).
  • Analysis of gene expression related to immune regulation and maturation, including Cd274, Pdcd1lg2, Cd200, Cd40, Ccr7, and Il12b.

Main Results:

  • A novel DC subset, mregDCs, was identified, co-expressing immunoregulatory and maturation genes.
  • The mregDC program is induced in conventional DC1s and DC2s upon tumor antigen uptake.
  • Upregulation of programmed death-ligand 1 in mregDCs is AXL-dependent, while IL-12 production is negatively regulated by IL-4 signaling.
  • Blocking IL-4 enhanced IL-12 production by mregDC1s, increased effector T cells, and reduced tumor burden.

Conclusions:

  • A regulatory module associated with tumor antigen uptake impairs DC1 functionality in cancer.
  • Targeting the IL-4 signaling pathway in mregDCs can restore anti-tumor immunity.
  • These findings offer potential new strategies for improving the efficacy of cancer immunotherapy.